Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

PTD-DBM peptide icon, one bubble per amino acidPTD-DBM15 residues (approx.)RRRRRRRRYKQFRDHEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.

PTD-DBM

Anti-AgingResearch
~2-4 hours half-life (estimated)·Topical·12w on / 4w off

Also known as: PTD-DBM, CXXC5-Dvl disrupting peptide

One foundational study in mice. Zero human clinical trials. PTD-DBM (Protein Transduction Domain-fused Dishevelled Binding Motif) is a topical peptide designed at Yonsei University to reactivate Wnt/beta-catenin signaling in balding scalps by blocking the CXXC5-Dvl interaction. The 2017 mouse data [1] showed new follicle formation when combined with valproic acid. That result hasn't translated to humans yet, and the original developer has moved on to a small molecule successor called KY19382. Experimental hair loss researchers still test it, but community results have been overwhelmingly disappointing so far.

What Is PTD-DBM?

New follicle formation in a mouse wound model. That single result from 2017 put PTD-DBM on the map for experimental hair loss research.

PTD-DBM (Protein Transduction Domain-fused Dishevelled Binding Motif, CAS not yet assigned) is a synthetic peptide that blocks the protein-protein interaction between CXXC5 and Dishevelled (Dvl) at the upstream end of the Wnt/beta-catenin signaling pathway. CXXC5 is a zinc finger protein overexpressed in balding scalps. It suppresses Wnt signaling by sequestering Dvl. PTD-DBM competes for that binding site, restoring beta-catenin nuclear translocation and downstream transcription of hair growth genes.

Cho and colleagues at Yonsei University published the foundational study in the Journal of Investigative Dermatology (2017)[1]. Topical PTD-DBM combined with valproic acid produced wound-induced hair follicle neogenesis (WIHN) in mice within 28 days. The peptide also upregulated beta-catenin in cultured human dermal papilla cells. A 2023 paper [2] confirmed CXXC5 mediates DHT-induced alopecia via PGD2 signaling, adding mechanistic weight to the target.

Real-world use tells a different story. Community reports across tressless.com, HairLossTalk, and r/HairlossResearch consistently describe months of daily application with no visible results. Cold chain failures, concentration uncertainty, and the peptide's ~2.5 kDa molecular weight (limiting intact skin penetration) likely contribute to this gap. Dr. Kang-Yell Choi's lab has since pivoted to KY19382 [3], a small molecule that outperformed PTD-DBM plus valproic acid in a 2023 comparison. The peptide is no longer the active pipeline compound from its own creator.

How PTD-DBM Works

CXXC5 is the molecular brake. PTD-DBM removes it.

In healthy hair follicles, the Wnt/beta-catenin pathway drives the anagen (growth) phase of the hair cycle. Beta-catenin enters the nucleus, activates TCF/LEF transcription factors, and switches on genes responsible for follicle cycling and dermal papilla maintenance. In androgenetic alopecia, CXXC5 is overexpressed. This zinc finger protein binds to Dishevelled (Dvl), a key upstream scaffold in Wnt signaling, and blocks the pathway before it reaches beta-catenin.

PTD-DBM is a synthetic peptide engineered to mimic the Dvl-binding domain of CXXC5. It competes for the same binding site on Dvl, displacing CXXC5 and freeing the pathway. Beta-catenin accumulates, translocates to the nucleus, and reactivates downstream transcription. The PTD portion (an octa-arginine protein transduction domain) enables the peptide to cross cell membranes when applied topically.

Valproic acid enters the picture at a different node. VPA inhibits GSK-3-beta, the kinase that phosphorylates beta-catenin and tags it for degradation. PTD-DBM works upstream (removing CXXC5 from Dvl); VPA works downstream (preventing beta-catenin destruction). Mouse WIHN data from PMID 28595998 confirmed the combination outperformed either compound alone. That dual-node activation is the mechanistic rationale behind every community protocol pairing these two.

PTD-DBM Benefits

  • PTD-DBM benefits center on Wnt pathway reactivation and non-hormonal hair follicle stimulation.
  • Targets CXXC5-Dvl interaction directly, restoring Wnt/beta-catenin signaling in follicular cells where the pathway is suppressed [1].
  • No hormonal mechanism. No DHT manipulation, no sexual side effects. Preferred by users who avoid finasteride for this reason.
  • Stimulated wound-induced hair follicle neogenesis (WIHN) in the 2017 mouse model when combined with valproic acid, producing visible new follicles within 28 days.
  • Upregulated beta-catenin and collagen production in cultured human dermal papilla cells (Cho et al., J Invest Dermatol 2017).
  • Theoretically additive with minoxidil and finasteride. Three entirely distinct mechanisms (vasodilation, 5-alpha-reductase inhibition, CXXC5-Dvl disruption) with no pharmacological conflict between them.
  • Compatible with existing topical peptide stacks. No known interaction with GHK-Cu or other scalp peptides in community-reported protocols.

PTD-DBM: Science vs Community Consensus

Divergent
Scientific Evidence
Weak
Based on 6 key studies·Research only

Preclinical evidence only.

Dosing studied: No validated human dose. From clinic and product guidance: 0.5-1 mg/mL topical, once daily. Mouse study used 10 mM (~25 mg/mL) every other day: not translatable to human topical dosing.
Read the evidence (key study, limitations)

Foundational 2017 paper [1] demonstrated PTD-DBM + valproic acid produces wound-induced hair neogenesis (WIHN) in mice and upregulates beta-catenin in human dermal papilla cells in culture. No human clinical trial published. Original developer (Dr. Kang-Yell Choi, Yonsei University) has abandoned PTD-DBM for small molecule successor KY19382. Evidence base is narrow (~5 direct papers, ~15 broader CXXC5/Wnt papers).

Key Study

PMID 28595998: Cho YC et al. J Invest Dermatol 2017. First demonstration: topical PTD-DBM + valproic acid promotes WIHN in a mouse wound model and upregulates beta-catenin/Wnt target genes in human dermal papilla cells in vitro. Remains the sole foundational efficacy study.

Limitations

No human clinical trial. All efficacy data from murine wound models or cell culture. Small molecule successor KY19382 (PMID 33751552) outperformed PTD-DBM+VPA in 2023 (PMC9954685) and its developer has pivoted away from the peptide. High MW (~2.5 kDa) limits topical skin penetration without microneedling. No formal carcinogenicity study; Wnt/beta-catenin is proto-oncogenic when dysregulated. Half-life and topical PK not established.

Community Experience
Weak
2.5/5
Based on low: tressless.com community threads, HairLossTalk.com forums, r/HairlossResearch. No dedicated subreddit. Sentiment 2.5/5.

Theoretically exciting but practically disappointing.

Community dosing: 0.5-1 mg/mL topical daily (spray or serum); microneedling-assisted protocols apply same concentration immediately post-needling 1-2x/week
Read the reports (what users report 3, common issues 6)

Most consistent real-world finding: no visible results after months of use. Sourcing difficulties (cold chain, stability, concentration uncertainty) undermine real-world reliability. Small experimental contingent continues testing PTD-DBM + VPA + microneedling stacks with inconclusive results.

What users report (3)
  • Non-hormonal mechanism: no DHT/sexual side effect risk; preferred by finasteride-avoiders
  • Theoretically additive with minoxidil and finasteride via entirely distinct pathway
  • Compatible topical stack with GHK-Cu and microneedling protocols: no pharmacological conflict
Common issues (6)
  • No noticeable results in human users: most consistent community finding after months of daily use
  • High cost ($86-89 per 5 mg vial) with no certainty about effective human concentration or stability
  • Cold chain rarely maintained in shipping: degradation-prone peptide (~2.5 kDa) rendered inactive by improper storage
  • Cosmetic serums (e.g., 0.002% over-the-counter formulations) are 100-500x below research concentrations: not research-grade
  • Weekly dosing (from misleading guides including peptides.ts template) produces subclinical exposure
  • Possible increased scalp oiliness from CXXC5 blockade in sebaceous glands
Science & Community Diverge

Preclinical science demonstrates mechanistic efficacy in mice and human dermal papilla cells in culture, but community human use consistently fails to replicate meaningful results. No human trial bridges this gap. Divergence likely reflects: inadequate topical bioavailability without microneedling, widespread daily vs. weekly dosing confusion, product degradation from cold chain failures, and genuine mouse-to-human translatability challenges. Dr. Choi's lab pivot to KY19382 implicitly acknowledges these translation limitations.

PTD-DBM Dosage Guide

SpeculativeVery limited human data: dose based on preclinical research
LevelDoseFrequency
Beginner500 mcgDaily
Moderate1 mgDaily
Aggressive1 mgDaily
Note:

Your first vial is probably going to be a 5 mg lyophilized powder. Reconstitute in 10 mL of sterile water for a 0.5 mg/mL solution, or 5 mL for 1 mg/mL. Draw 1 mL per session with a syringe and apply directly to the scalp (no injection needed). That gives you 500 mcg per application at the lower concentration. A 5 mg vial at daily use lasts about 10 days at 0.5 mg/mL, or 5 days at 1 mg/mL.

The thing most beginners miss: this peptide degrades fast once reconstituted. Use it within 14 days at 2 to 8 degrees Celsius. Lyophilized stock should stay at minus 20 degrees. If a vial arrives without an ice pack, assume the product is compromised.

Daily application is the community standard. Weekly dosing (which some guides mistakenly recommend) produces subclinical Wnt exposure. Apply to clean, dry scalp; avoid washing for 4 hours. If you're adding valproic acid, apply PTD-DBM first, wait 15 to 20 minutes, then apply VPA.

Cycling Protocol

On Period
12 weeks
Off Period
4 weeks

Apply topically for 12 weeks to assess response. Can be extended if well-tolerated. Frequency may be reduced from weekly to every 10-15 days after 2 months. Often paired with valproic acid topical and microneedling 1-2x/week.

Calculate your PTD-DBM dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

PTD-DBM Protocols by Goal

beginnerCommunity12 weeks minimum
Foundation
Wk 1-4
0.5 mg/mL topical (500 mcg per 1 mL application) · Once daily · Topical scalp spray
Active
Wk 5-12
0.5-1 mg/mL topical (500-1,000 mcg per 1 mL application) · Once daily · Topical scalp spray

Expected: Reduced shedding in responders; modest density improvement possible by weeks 9-12. Majority of users report no visible change at this dose without VPA or microneedling.

Monitor: Photograph scalp at baseline and every 4 weeks under identical lighting and angle. Use trichoscopy ruler if available.

How to Use PTD-DBM

  1. 1
    Step 1

    Reconstitute one 5 mg vial with 10 mL sterile water for 0.5 mg/mL concentration (or 5 mL for 1 mg/mL). Gently swirl until dissolved. Do not shake.

  2. 2
    Step 2

    Draw 1 mL of solution using a 1 mL syringe (no needle needed for topical use). At 0.5 mg/mL, 1 mL contains 500 mcg. At 1 mg/mL, 1 mL contains 1,000 mcg. On a standard 1 mL syringe, draw to the 100 unit mark for a full 1 mL application.

  3. 3
    Part your hair to expose the scalp in the target area

    Apply the solution directly to the scalp using the syringe tip. Distribute evenly across thinning zones. Massage gently for 30 seconds.

  4. 4
    Step 4

    Allow 15 to 20 minutes of absorption time before applying any additional topicals (valproic acid, minoxidil, GHK-Cu). Do not wash hair for at least 4 hours.

  5. 5
    Step 5

    If using microneedling (0.5 to 1.5 mm depth, 1 to 2 times per week), apply PTD-DBM within 15 minutes of needling while micro-channels remain open. This dramatically improves dermal papilla penetration.

  6. 6
    Store reconstituted solution at 2 to 8 degrees Celsius

    Discard after 14 days. Keep lyophilized vials at minus 20 degrees Celsius for long-term storage.

Alternative Routes

Topical scalp spray (daily)

0.5-1 mg/mL concentration; 1 mL per session (500-1,000 mcg); penetration limited by intact skin barrier

Reconstitute 5 mg vial in 10 mL sterile water (0.5 mg/mL) or 5 mL (1 mg/mL). Apply with syringe tip or transfer to spray bottle. Part hair to expose scalp; apply directly to scalp tissue. Massage gently. No wash for 4h.

Microneedling-assisted topical delivery

Same concentration (0.5-1 mg/mL); dramatically enhanced follicle-level delivery via micro-channels. Apply within 15 min of needling session while channels are open.

0.5mm depth for beginners; 1.0-1.5mm for experienced users targeting dermal papilla. 1-2x/week cadence maximum. Apply PTD-DBM immediately post-needling.

Compounded clinic serum

Concentration determined by prescribing physician; may include stabilizers or penetration enhancers absent in DIY reconstitution

Clinic protocols typically require consultation ($250+) plus monthly product cost. More consistent formulation than DIY; physician monitoring of scalp response. Limited availability: few practitioners familiar with topical peptide hair protocols.

PTD-DBM Stacking Protocols

Works With

Valproic Acid (Topical 0.1-0.3%)

Best-evidenced combination. VPA inhibits GSK-3beta (downstream beta-catenin degrader); PTD-DBM removes CXXC5 suppression of Dvl (upstream Wnt activator). Mouse WIHN data confirms combination outperforms either agent alone. Only combination with published evidence for this peptide.

0.1-0.3% VPA topical applied after PTD-DBM (15-20 min gap); daily application.

GHK-Cu

Complementary scalp and follicle support without Wnt pathway overlap. GHK-Cu promotes dermal collagen, elastin, and scalp tissue health. Community commonly combines both in topical hair protocols. No pharmacological conflict.

Apply GHK-Cu first (lower MW), allow 10-15 min, then PTD-DBM

Minoxidil (Topical 2-5%)

Entirely different mechanism (vasodilation / anagen phase extension via potassium channels). No pharmacological conflict with PTD-DBM CXXC5-Dvl disruption. Theoretically additive for a broad AGA approach.

Apply minoxidil at a separate time from PTD-DBM (2h gap minimum) to prevent formulation interference

Avoid

Topical Corticosteroids (same scalp area)

May attenuate Wnt/beta-catenin pathway activation. Concurrent application to the same scalp areas may counteract PTD-DBM mechanism.

Systemic Wnt Pathway Activators (Lithium, systemic GSK-3beta inhibitors)

Additive Wnt activation may dysregulate the proto-oncogenic pathway. Topical VPA (low systemic absorption) is acceptable; systemic GSK-3beta inhibitors or high-dose lithium create unpredictable additive risk with insufficient safety data.

Estimated Cost

Compounded
Research-grade 5 mg vial: $86-89 (typical Q1 2026 price). 2 and 10 mg vials are also listed. Compounding clinic protocols: ~$250 consultation + ~$200/month (community report, HairLossTalk). Over-the-counter cosmetic serums (0.002%): not research-grade concentration.

Pricing updated 2026-04-09

PTD-DBM Side Effects

Wnt/beta-catenin is a proto-oncogenic pathway. That fact deserves attention before anything else. No formal carcinogenicity study has been conducted for PTD-DBM. Chronic activation of Wnt signaling is linked to several cancer types. Topical application limits systemic exposure, and no cancer signal appeared in mouse studies, but the absence of a long-term safety study is a genuine gap. Anyone with a personal or family history of Wnt-pathway cancers should exercise particular caution.

No human clinical trial has been published. The total human evidence base consists of in vitro dermal papilla cell culture data. Side effect information comes entirely from animal models and community self-reports across a small user base (tressless.com, HairLossTalk forums, r/HairlossResearch).

Scalp irritation and redness are the most commonly reported issues. These occur primarily in users combining PTD-DBM with microneedling, which creates micro-channels in the scalp. Irritation from microneedling alone can be difficult to distinguish from peptide-related reactions. Users running the VPA combination protocol report higher irritation rates than PTD-DBM alone.

Increased scalp oiliness is mechanistically expected. CXXC5 is expressed in sebaceous glands, and blocking it may dysregulate sebum production. Several community reports describe new or worsening oiliness after 4 to 8 weeks of daily use. If seborrheic dermatitis develops, discontinue immediately.

Allergic reactions to the peptide itself appear rare in community reports. No systemic side effects have been documented, consistent with minimal absorption from topical application.

When to stop: new or changing scalp lesions of any kind (given the Wnt proto-oncogenicity concern), persistent dermatitis, significant folliculitis, or seborrheic dermatitis that worsens despite reducing application frequency. Any new scalp lesion warrants dermatologist evaluation.

Contraindications: pregnancy or breastfeeding (no safety data), active scalp infections or open wounds, known hypersensitivity to PTD-DBM or formulation excipients, history of skin cancer or active malignancy, and children under 18.

Common Issues & Solutions

No results at 8-12 weeks: most common issue. Confirm daily (not weekly) application: weekly dosing produces subclinical Wnt exposure. Check that the cold chain was maintained during shipping. Add VPA topical and/or microneedling to improve follicle penetration.

Scalp irritation or redness: expected with microneedling. Allow 24-48h between needling sessions if significant. Reduce needling depth or frequency. Separate VPA and PTD-DBM applications if combined irritation is occurring.

Increased scalp oiliness: mechanistically expected from CXXC5 blockade in sebaceous glands (CXXC5 regulates sebum). Reduce application frequency. Discontinue if seborrheic dermatitis develops or worsens.

Product degradation / no effect despite correct protocol: reconstituted PTD-DBM degrades rapidly due to high MW (~2.5 kDa). Use within 14 days at 2-8°C. Lyophilized stock must stay at -20°C. If the product arrived without an ice pack or cold chain confirmation, assume degradation.

Application order confusion: apply PTD-DBM first to clean dry scalp; wait 15-20 min; then apply valproic acid or other topicals. Do not mix compounds in the same syringe or container.

Ask AI about this page

Ask AI for a second opinion on PTD-DBM dosing and side effects

Contraindications

  • Pregnancy or breastfeeding: no safety data available in these populations
  • Active scalp infections, open wounds, or dermatitis: resolve before beginning treatment
  • Known hypersensitivity to PTD-DBM or any formulation excipients
  • History of skin cancer or active malignancy: Wnt/β-catenin activation may theoretically promote tumor growth
  • Children and adolescents under 18: not studied in pediatric populations

Drug Interactions

  • Valproic acid (topical): intentionally combined for stronger Wnt activation; monitor for increased scalp irritation
  • Finasteride/dutasteride: may be used concurrently as they target different pathways (5α-reductase vs. CXXC5-Dvl); no known direct interaction
  • Minoxidil: can be used alongside PTD-DBM; separate application times by at least 2 hours to avoid formulation interference
  • Immunosuppressants (topical corticosteroids): may attenuate Wnt pathway activation; avoid concurrent application to the same area
  • Other Wnt pathway activators (lithium, GSK-3β inhibitors): potential additive Wnt signaling; use with caution due to limited safety data

Product Quality

Recommended Monitoring

TestWhenTarget
Scalp photographyBaseline, then monthly throughout protocolNot listed
Trichoscopy / dermatoscopyBaseline and at week 12 (week 24 if continuing)Not listed
Scalp symptom self-assessmentWeekly throughout protocolNo new oiliness, lesions, dermatitis, or folliculitis. Discontinue if seborrheic dermatitis develops.
Scalp photography

Objective documentation of density changes. Standardize lighting, angle, and hair parting at every session for valid comparison.

Trichoscopy / dermatoscopy

Detects vellus-to-terminal conversion and early follicle density changes invisible to the naked eye. Recommended for WIHN protocol users.

Scalp symptom self-assessment

CXXC5 expressed in sebaceous glands: chronic blockade may increase sebum or worsen seborrheic dermatitis. Early detection prevents escalation.

PTD-DBM Before and After

Weeks 1-4

Scalp adjusts to topical application. No visible hair changes yet. Mild redness possible with microneedling. Wnt/β-catenin signaling begins to reactivate in follicular cells.

Weeks 5-8

Early follicle stimulation may begin. Vellus (fine) hair density may increase in treated areas. Continued consistent application is critical for cumulative signaling effects.

Weeks 9-12

Visible improvements in hair density and thickness reported in animal models at comparable timepoints. Terminal hair conversion from vellus hairs may begin. Best results seen with PTD-DBM + valproic acid combination.

Months 4-6

Continued follicle maturation and hair cycle normalization. New follicle formation (neogenesis) possible in areas with microneedling. Application frequency can be reduced to every 10-15 days for maintenance.

Months 6+

Maintenance phase. Ongoing application at reduced frequency to preserve gains. Long-term human efficacy data is still limited: results extrapolated from preclinical models.

What to Expect

Weeks 1 through 4: Scalp adjustment, nothing visible. Wnt/beta-catenin signaling starts reactivating in follicular cells based on mouse model timelines, but you won't see or feel anything meaningful. Mild redness is common if you're microneedling. Some users notice increased scalp oiliness during this window.

Weeks 5 through 8: Early follicle signaling may begin at the cellular level. Mouse data shows activation markers appearing in this window. Community reports still describe no visible changes for the majority of users. A few report reduced shedding, but no confirmed regrowth at this stage.

Weeks 9 through 12: This is the peak response window in preclinical models. The mouse wound model showed visible new follicle formation at comparable timepoints with the PTD-DBM plus VPA combination. Most human users still report no visible change. A small minority describe subtle density increases or early vellus hair changes, not terminal hair.

Months 4 through 6: Assessment time. Most non-responders stop around month 4. Users who continue report maintenance of any early gains. Very few describe terminal hair regrowth that competes with minoxidil or finasteride benchmarks. Application frequency can drop to every 10 to 15 days for maintenance.

Months 6 and beyond: Maintenance phase for committed users. Long-term human efficacy data doesn't exist. Results at this stage are extrapolated from preclinical models. Ongoing application at reduced frequency preserves whatever Wnt signaling state was achieved.

Detailed Timeline: Science vs Community

Weeks 1-4
Science

Wnt/beta-catenin signaling begins reactivating in follicular cells per mouse timeline. No observable follicle changes at this stage in any model.

Community

No visible changes. Users establish routine and assess scalp tolerance. Mild redness common with microneedling. Some notice increased oiliness.

Weeks 5-8
Science

Mouse data: early follicle activation markers appear in this window. Vellus hair density may increase in treated areas based on mouse model timeline extrapolation.

Community

Still no visible changes for the majority. Rare users report reduced shedding. No confirmed regrowth reports at this stage.

Weeks 9-12
Science

Mouse wound model shows visible new follicle formation at comparable timepoint with PTD-DBM + VPA combination. Terminal hair conversion from vellus may begin.

Community

Majority report no visible change. A small minority report subtle density increase. Most who will see any results note early vellus changes here: not terminal hair.

Months 4-6
Science

New follicle maturation and hair cycle normalization (if follicle neogenesis occurred). Mouse data shows continued density improvement in WIHN responders.

Community

Most non-responders discontinue around month 4. Users who continue report maintenance of early gains. Very few report meaningful terminal hair regrowth vs. minoxidil or finasteride benchmarks.

Months 6+
Science

Ongoing application to preserve Wnt signaling state. Reduced frequency (every 10-15 days) for maintenance per cycling protocol.

Community

Long-term human efficacy data absent. Results extrapolated from preclinical models. Users at this stage typically committed to experimental stack despite uncertain outcomes.

Pharmacokinetics

Half-Life
3h
Bioavailability
Topical: variable, enhanced by microneedling; systemic absorption minimal
Tmax
Not established (topical local action)
Data Confidence
low

Source: Estimated from general small peptide degradation kinetics; no specific PK study for PTD-DBM published. Topical residence time likely longer due to skin depot effect.

Pharmacokinetics: Active Dose Over Time

t½ = ~2-4 hours (estimated, topical peptide)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
15
Sequence
RRRRRRRRYKQFRDH
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: Not assigned (research peptide, no CAS registry entry found)

Who Should Consider PTD-DBM

  • Adults with androgenetic alopecia (male or female pattern hair loss)
  • Individuals with CXXC5-mediated Wnt pathway suppression in scalp tissue
  • Patients seeking non-systemic, topical alternatives to finasteride or minoxidil
  • Adults interested in wound-induced hair follicle neogenesis protocols
  • Individuals combining peptide therapy with microneedling for hair restoration

Related Peptides

What Changed for PTD-DBM

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 20266 Citations

References

  1. [1]Targeting of CXXC5 by a Competing Peptide Stimulates Hair Regrowth and Wound-Induced Hair Neogenesis (J Invest Dermatol 2017) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD2 (Cells 2023) (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]KY19382, a novel activator of Wnt/beta-catenin signalling, promotes hair regrowth and hair follicle neogenesis (Ryu et al., Br J Pharmacol 2021) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Room temperature up to 1 month, refrigerated up to 12 months
After Reconstitution
Refrigerate at 2-8°C, use within 4 weeks
Temperature
2-8°C (36-46°F) after reconstitution

Frequently Asked Questions

Preclinical only as of 2026. The foundational 2017 paper (PMID 28595998) tested in mouse models and human dermal papilla cells in culture, not living human subjects. No human clinical trial has been published. Dr. Choi's lab has since moved on to KY19382, a small molecule successor, as their clinical candidate.

Entirely distinct mechanisms. Minoxidil is vasodilation that extends the growth phase. Finasteride reduces DHT to slow follicle miniaturization. PTD-DBM removes a molecular brake on the Wnt/beta-catenin pathway that governs follicle cycling. No pharmacological conflict between the three: stacking is theoretically additive, though no combination data exists.

They hit different nodes of the same Wnt pathway. VPA inhibits GSK-3-beta, which degrades beta-catenin downstream. PTD-DBM removes CXXC5's suppression of Dishevelled upstream. Mouse wound-induced hair neogenesis data confirms the combination outperforms either agent alone. It's the only combination with published evidence for this peptide, from mouse studies.

It's a fair question. Wnt/beta-catenin is proto-oncogenic when dysregulated. However, topical application is unlikely to reach meaningful systemic levels, no cancer signal has appeared in mouse studies, and CXXC5 blockade is locally targeted. Formal carcinogenicity studies haven't been done. If you have a personal or family history of Wnt-pathway cancers, exercise particular caution.

Dr. Choi explained in a Follicle Thought Q&A that a small molecule drug is more commercially viable: peptides face stability, shelf life, manufacturing cost, and skin penetration challenges. KY19382 was developed as the successor that simultaneously inhibits both CXXC5-Dvl and GSK-3-beta. A 2023 paper showed it outperformed PTD-DBM+VPA. The peptide is no longer the active pipeline compound.